Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463129 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4PARP1 | |
| SCHEMBL18042843 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18042846 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5574863 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4PARP1 | |
| SCHEMBL18594506 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL15711294 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL17120406 | 0.77 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13108774 | 0.77 | EGFR (0.47) | — | |
| SCHEMBL13108772 | 0.77 | EGFR (0.47) | — | |
| SCHEMBL23620515 | 0.77 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-10988501-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. | 2021-04-27 | — | — | US | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-7671085-B2 | Non-steroidal farnesoid X receptor modulators and methods for the use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-7381825-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7375228-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080063628-A1 | METHODS TO PROMOTE CELL DIFFERENTIATION | LIFESCAN, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | CHRNB2 1682/4885CHRNB4 2143/4885CHRNA3 2345/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CHRNB2 4052/4885CHRNB4 4502/4885CHRNA3 4195/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | CHRNB2 3293/4885CHRNB4 2761/4885CHRNA3 1700/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | CHRNB2 3937/4885CHRNB4 4363/4885CHRNA3 3822/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | CHRNB2 3862/4885CHRNB4 4246/4885CHRNA3 4260/4885 |
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | CHRNB2 3871/4885CHRNB4 4052/4885CHRNA3 3481/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | CHRNB2 168/4885CHRNB4 95/4885CHRNA3 70/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CHRNB2 3850/4885CHRNB4 3748/4885CHRNA3 1968/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CHRNB2 4548/4885CHRNB4 4312/4885CHRNA3 3679/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CHRNB2 4658/4885CHRNB4 4654/4885CHRNA3 4623/4885 |
| US-10988501-B2 | Reversibly blocked nucleoside analogues and their use | NSUN2, NME2, ADAR | CHRNB2 1950/4885CHRNB4 1588/4885CHRNA3 2090/4885 |
| US-20080063628-A1 | METHODS TO PROMOTE CELL DIFFERENTIATION | CTCF, CBX2, ZMYND8 | CHRNB2 1287/4885CHRNB4 1579/4885CHRNA3 2085/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | CHRNB2 2125/4885CHRNB4 2644/4885CHRNA3 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.